Sionna Therapeutics, Inc. (NASDAQ:SION) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Sionna Therapeutics, Inc. (NASDAQ:SION) has received a consensus recommendation of “Moderate Buy” from the eleven research firms that are covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, six have issued a buy recommendation and three have assigned a strong buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $53.00.

A number of analysts have issued reports on SION shares. Guggenheim boosted their price objective on shares of Sionna Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Citizens Jmp started coverage on shares of Sionna Therapeutics in a report on Tuesday, February 24th. They issued a “market outperform” rating and a $63.00 price objective for the company. JonesTrading boosted their price objective on shares of Sionna Therapeutics from $52.00 to $63.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. UBS Group reissued a “buy” rating on shares of Sionna Therapeutics in a report on Monday, March 2nd. Finally, BTIG Research reissued a “buy” rating and issued a $58.00 price objective on shares of Sionna Therapeutics in a report on Monday, April 27th.

Sionna Therapeutics Price Performance

NASDAQ SION opened at $44.23 on Monday. The company has a market capitalization of $2.00 billion, a P/E ratio of -22.68 and a beta of 1.35. Sionna Therapeutics has a 12-month low of $11.77 and a 12-month high of $46.46. The firm has a 50-day moving average price of $38.55 and a two-hundred day moving average price of $39.36.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.15. Equities analysts expect that Sionna Therapeutics will post -2.32 EPS for the current year.

Insider Activity at Sionna Therapeutics

In other news, Director Peter A. Thompson sold 235,863 shares of the business’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $44.64, for a total value of $10,528,924.32. Following the completion of the transaction, the director directly owned 3,247,025 shares in the company, valued at approximately $144,947,196. The trade was a 6.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 235,863 shares of the business’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the completion of the transaction, the director owned 3,247,025 shares of the company’s stock, valued at $144,947,196. The trade was a 6.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,131,856 shares of company stock valued at $50,834,773 over the last 90 days. Corporate insiders own 3.90% of the company’s stock.

Hedge Funds Weigh In On Sionna Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. GF Fund Management CO. LTD. acquired a new position in shares of Sionna Therapeutics in the 4th quarter valued at approximately $36,000. Russell Investments Group Ltd. acquired a new position in shares of Sionna Therapeutics in the 3rd quarter valued at approximately $30,000. Balyasny Asset Management L.P. acquired a new position in shares of Sionna Therapeutics in the 4th quarter valued at approximately $58,000. BNP Paribas Financial Markets acquired a new position in shares of Sionna Therapeutics in the 2nd quarter valued at approximately $31,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Sionna Therapeutics in the 4th quarter valued at approximately $89,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.